Unit: Technical Assessment Unit

Public assessment report for biological products

Tepkinly 4 mg and 48 mg

Administrative information:

Trade name of the medicinal product:	Tepkinly 4 mg/0.8ml Tepkinly 48mg
INN (or common name) of the active substance(s):	Epcoritamab
Manufacturer of the finished product	Vetter Pharma-fertigung GmbH and Co.KG, Eisenbahnstrasse 2-4, 88085 Langenargen, Baden-Wuerttemberg, - GERMANY ;
Marketing Authorization holder	Abbvie Deutschland GmbH and Co KG, Knollstrasse, 67061 Ludwigshafen - GERMANY
Applied Indication(s):	Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. Treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
Pharmaceutical form(s) and strength(s):	Solution for injection 5 mg/ml (4mg epcoritamab/0.8ml) 60 mg/ml (48mg epcoritamab/0.8ml)
Route of administration	S.C
Registration track	Reliance Level 1
Type of registration (EMA/FDA – Local)	EMA approved

List of abbreviations

SC	Subcutaneous
ADCP	antibody-dependent cellular phagocytosis
FL	follicular lymphoma
CDC	cellular cytotoxicity
ADCC	antibody-dependent cellular cytotoxicity
R/R DLBCL	relapsed or refractory diffuse large B-cell lymphoma
ICANS	immune effector cell-associated neurotoxicity syndrome
bsAb	bi-specific antibody
CTLS	clinical tumor lysis syndrome

DS	Drug substance
GMP	Good manufacturing practice
CRS	cytokine release syndrome
DP	Drug Product
CHO	Chinese hamster ovary
BIs	biological intermediates

Table of contents

Dossier initial submission and evaluation process:

The file evaluated according to EDA Reliance Model on 13.2.2025 & the company submitted data which are the followings:

-Complete CTD file.
-EMA unreadcted assessment report

1. General introduction about the product including brief description of the AI, its mode of action and indications

-Epcoritamab, also referred to as GEN3013 or DuoBody®-CD3×CD20, is s a humanized IgG1 bispecific antibody that binds to a specific extracellular epitope of CD20 on B cells and to CD3 on T cells.
-Epcoritamab simultaneously binds to CD3 on T-cells and CD20 on malignant B-cells, inducing CD20-specific T-cell activation and T-cell-mediated cytotoxicity. Epcoritamab carries inertness mutations to silence Fc-mediated effector functions for direct immune effector mechanisms, such as antibody-dependent cellular cytotoxicity (ADCC), complement dependent cellular cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP). It is indicated as monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy."
-The active substance epcoritamab (INN) is a bi-specific antibody (bsAb) generated by a

process called controlled Fab-arm exchange of the two parental antibodies, **intermediates 3001d and 3005a**. The parental antibodies, 3001d and 3005a, are separately produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology and purified as biological intermediates (BIs), at a concentration of 20 mg/mL

Quality aspects:

- **Manufacturer**

- Drug substance (DS) is manufactured according to current Good Manufacturing Practices (cGMP) at Rentschler biopharma Inc. 27 Maple street Milford MA 01757 - UNITED STATES OF AMERICA
-Tepkinly as finished product is manufactured at Vetter Pharma-fertigung GmbH and Co.KG, Eisenbahnstrasse 2-4, 88085 Langenargen, Baden-Wuerttemberg, - GERMANY
- Manufacturing of both DS and DP are performed in accordance with cGMP regulations.

- **Stability**

Drug substance:

Approved Storage Conditions: Store at ≤-60 °C
Approved Shelf Life:30 months

Drug Product:

Tepkinly 4mg/0.8ml:

Approved Storage Conditions:
-Store and transport refrigerated (2 - 8 °C).
-Do not freeze.
-Keep the vial in the outer carton in order to protect from light
Approved Shelf Life
Finished product:24 months

Tepkinly 48mg/0.8ml
Approved Storage Conditions:
-Store and transport refrigerated (2 - 8 °C).
-Do not freeze.
-Keep the vial in the outer carton in order to protect from light
Approved Shelf Life
Finished product:24 months

2. **Non –Clinical aspect & Clinical aspect:**

-Overall, the safety profile is in line with what can be expected for a bispecific CD3/CD20-directed T-cell engager and the preclinical toxicity findings. Due to the MoA of activating T-cells CRS, ICANS, and CTLS are to be expected, as are cytopenias and infections with bispecific antibodies.
-the overall benefit/risk of Tepkinly 4mg./0.8ml., solution for injection SC (as a monotherapy) is favorable in the treatment of:

-adult patients with relapsed or refractory diffuse large B-cell lymphoma **(R/R DLBCL)** after two or more lines of prior systemic therapy.
-adult patients with relapsed or refractory follicular lymphoma **(FL)** after two or more lines of systemic therapy.

4.General Conclusion and Recommendations if any:

Based on the review of CTD modules and other supplementary documents, the product is approved.

For more information, please visit EMA published assessment report link:

https://www.ema.europa.eu/en/documents/product-information/tepkinly-epar-product-information_en.pdf